Early administration of the GIP receptor antagonist (Pro3)GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity.

  • P.R. Flatt
  • , N. Irwin
  • , P.L. McClean
  • , Brian Green
  • , V.A. Gault
  • , C.J. Bailey
  • , F.P.M. O'Harte

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)108
JournalDiabetologia
Volume49
Issue numberS1
Publication statusPublished - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this